» Articles » PMID: 35580931

Mitoribosomal Defects Aggravate Liver Cancer Via Aberrant Glycolytic Flux and T Cell Exhaustion

Abstract

Background: Mitochondria are involved in cancer energy metabolism, although the mechanisms underlying the involvement of mitoribosomal dysfunction in hepatocellular carcinoma (HCC) remain poorly understood. Here, we investigated the effects of mitoribosomal impairment-mediated alterations on the immunometabolic characteristics of liver cancer.

Methods: We used a mouse model of HCC, liver tissues from patients with HCC, and datasets from The Cancer Genome Atlas (TCGA) to elucidate the relationship between mitoribosomal proteins (MRPs) and HCC. In a mouse model, we selectively disrupted expression of the mitochondrial ribosomal protein CR6-interacting factor 1 (CRIF1) in hepatocytes to determine the impact of hepatocyte-specific impairment of mitoribosomal function on liver cancer progression. The metabolism and immunophenotype of liver cancer was assessed by glucose flux assays and flow cytometry, respectively.

Results: Single-cell RNA-seq analysis of tumor tissue and TCGA HCC transcriptome analysis identified mitochondrial defects associated with high-MRP expression and poor survival outcomes. In the mouse model, hepatocyte-specific disruption of the mitochondrial ribosomal protein CRIF1 revealed the impact of mitoribosomal dysfunction on liver cancer progression. deficiency promoted programmed cell death protein 1 expression by immune cells in the hepatic tumor microenvironment. A [U-C]-glucose tracer demonstrated enhanced glucose entry into the tricarboxylic acid cycle and lactate production in mice with mitoribosomal defects during cancer progression. Mice with hepatic mitoribosomal defects also exhibited enhanced progression of liver cancer accompanied by highly exhausted tumor-infiltrating T cells. deficiency induced an environment unfavorable to T cells, leading to exhaustion of T cells via elevation of reactive oxygen species and lactate production.

Conclusions: Hepatic mitoribosomal defects promote glucose partitioning toward glycolytic flux and lactate synthesis, leading to T cell exhaustion and cancer progression. Overall, the results suggest a distinct role for mitoribosomes in regulating the immunometabolic microenvironment during HCC progression.

Citing Articles

Bioinformatics analysis of mitochondrial metabolism-related genes demonstrates their importance in renal cell carcinoma.

Ahmadi M, Motallebinezhad M, Mousavi P, Miladipour A, Fooladgar S, Ghafouri-Fard S Discov Oncol. 2025; 16(1):28.

PMID: 39789365 PMC: 11717778. DOI: 10.1007/s12672-025-01780-4.


Co-regulation and synteny of GFM2 and NSA2 links ribosomal function in mitochondria and the cytosol with chronic kidney disease.

Zhang M, Hogstrand C, Pontrelli P, Malik A Mol Med. 2024; 30(1):176.

PMID: 39396937 PMC: 11476648. DOI: 10.1186/s10020-024-00930-8.


Elucidating the role of S100A10 in CD8 T cell exhaustion and HCC immune escape via the cPLA2 and 5-LOX axis.

Wang G, Shen X, Jin W, Song C, Dong M, Zhou Z Cell Death Dis. 2024; 15(8):573.

PMID: 39117605 PMC: 11310305. DOI: 10.1038/s41419-024-06895-0.


DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression.

Tan S, Zhang X, Guo X, Pan G, Yan L, Ding Z Cell Death Dis. 2024; 15(7):540.

PMID: 39080251 PMC: 11289107. DOI: 10.1038/s41419-024-06912-2.


Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment.

Zhang F, Guo J, Yu S, Zheng Y, Duan M, Zhao L Cancer Commun (Lond). 2024; 44(9):929-966.

PMID: 38997794 PMC: 11492308. DOI: 10.1002/cac2.12591.


References
1.
Li X, Wang M, Li S, Chen Y, Wang M, Wu Z . HIF-1-induced mitochondrial ribosome protein L52: a mechanism for breast cancer cellular adaptation and metastatic initiation in response to hypoxia. Theranostics. 2021; 11(15):7337-7359. PMC: 8210597. DOI: 10.7150/thno.57804. View

2.
Lee Y, Lim J, Jeoun U, Min S, Lee E, Kwon S . Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness. J Biol Chem. 2017; 292(49):20208-20217. PMC: 5724007. DOI: 10.1074/jbc.M117.809012. View

3.
Ma L, Hernandez M, Zhao Y, Mehta M, Tran B, Kelly M . Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell. 2019; 36(4):418-430.e6. PMC: 6801104. DOI: 10.1016/j.ccell.2019.08.007. View

4.
Menezes M, Guo Y, Zhang J, Riley L, Cooper S, Thorburn D . Mutation in mitochondrial ribosomal protein S7 (MRPS7) causes congenital sensorineural deafness, progressive hepatic and renal failure and lactic acidemia. Hum Mol Genet. 2015; 24(8):2297-307. DOI: 10.1093/hmg/ddu747. View

5.
Pfister D, Gonzalo Nunez N, Pinyol R, Govaere O, Pinter M, Szydlowska M . NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592(7854):450-456. PMC: 8046670. DOI: 10.1038/s41586-021-03362-0. View